Liraglutide Improves Non-Alcoholic Fatty Liver Disease in Diabetic Mice by Modulating Inflammatory Signaling Pathways
Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s224688
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Informa UK Limited